Review for Ukrainian pharmaceutical market of hepatotropic drugs and determining the volumes of their consumption during 2016–2018 years

Keywords: pharmaceutical market, hepatotropic drugs, ATC/DDD-methodology, consumption

Abstract

Hepatobiliary system and biliary tract diseases are common both in the world and in Ukraine (280,000 patients). According to the ATC classification, hepatotropic drugs are divided into three subgroups: А05А, А05В и А05С.

The aim of this study was to analyze the assortment of drugs for the pharmacotherapy of diseases of the liver and biliary tract and the volumes of their outpatient consumption during 2016‒2018 years in DDDs/1 000 inhabitants/day.

Drugs used for toxic hepatitis and presented in the pharmaceutical market of Ukraine were analyzed. The volumes of their outpatient consumption according to the ATC/DDD methodology based on the «Pharmstandard» system of the «Morion» company were determined, which also made it possible to analyze the assortment of drugs, to determine their dosage forms and manufacturing countries, and to analyze packaging prices.

ATC codes identified eight subgroups of drugs, and 158‒167 TNs represent them during 2016‒2018 years. The largest number of TNs were presented A05AA02 Ursodeoxycholic acid (27‒30 TNs, including 19‒21 of foreign origin), А05ВА03 Silymarin (21‒23 TNs, including 9‒11 of foreign origin) and А05ВА50 Different preparations (Essentiale and etc. 35, 37, 34 TNs, including 22, 23 и 20 of foreign origin). Among all drugs of hepatotropic action in Ukraine in the 2018 year, foreign drugs amounted 74 TNs (44,3%) and domestic – 93 TNs (55,7%). The drugs of this group are delivered to Ukraine from 17 countries, the largest part is delivered by Germany (32% of drugs), India (12%), Austria (9%), Italy (7%).

According to dosage forms, this group of drugs in 2018 was represented by 17 forms, mainly for the oral route (12 forms), 4 forms – for intravenous injection, and one – rectal suppository. The most consumed were: Different preparations including combined 3.9 DID, Silymarin – 1.48‒1.95 DID, Different preparations (Essentiale ® N, Essentiale ® Forte N, Hofitol) – 1.84‒2.08 DID.

The market of drugs used for diseases of the liver and biliary tract in Ukraine in the 2018 year was represented by eight subgroups of 167 TNs, 44.3% of which are foreign-made. Total preparations were presented in forms for the oral route (12 forms), 4 forms – for intravenous injection, and one – rectal suppository. Every year, the consumption of hepatotropic drugs increased slightly: from 8.12 DID to 9.23 DID.

References

1. Pestun I. V., Mnushko Z. M., Ievtushenko O. M. Marketing research of the Pharmaceutical market in Ukraine: Peculiarities, Trends, Problems, Tendencies // Res. J. Pharmacy and Technol. – 2019. – V. 12, N 4. – Р. 2049–2054. http://dx.doi.org/10.5958/0974-360X.2019.00339.1
2. Hala L., Panfilova H. Analysis of the creation of a modern pharmaceutical support system in ukraine in a retrospective development of the state and civil society relations // EUREKA: Health Sciences – 2019. – V. 5 – Р. 34–43. http://dx.doi.org/10.21303/2504-5679.2019.001003
3. Golubtsova K., Sahaidak-Nikitiuk R., Demchenko N. Study of factors affecting on the development of the pharmaceutical sector enterprises // ScienceRise. Pharmaceutical Science. – 2019. – V. 2. – Р. 28–32. https://doi.org/10.15587/2519-4852.2019.165640
4. Global Pharmaceuticals: 2018 Industry Statistics. – London: Hardman & Co. – 16 p.
5. Zhong H., Ouyang D. The gap analysis between Chinese pharmaceutical academia and industry from 2000 to 2018 // Scientometrics – 2020. – V. 122 – Р. 1113–1128. https://doi.org/10.1007/s11192-019-03313-7
6. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. – URL: http://www.drlz.com.ua
7. WHO Collaborating Centre for Drug Statistics Methodology. – URL: https://www.whocc.no/atc_ddd_index/
8. Nedashkivskyi S. M. Medykamentozno zumovleni urazhennia pechinky: pryntsypy diahnostyky, patolohichni zminy y pidkhody do likuvannia // Medytsyna nevidkladnykh staniv. – 2019. – Т. 2, № 97. – S. 63–70. – https://doi.org/10.22141/2224-0586.2.97.2019.161644
9. Pivtorak K. V. Osoblyvosti farmakoterapii nealkoholnoi zhyrovoi khvoroby pechinky u khvorykh iz nadlyshkovoiu masoiu tila ta ozhyrinniam // Zaporozhskyi med. zh. – 2017. – Т. 19, № 4 (103). – S. 520–524. https://doi.org/10.14739/2310-1210.2017.4.105301

10. Filippova O. Iu. Khvoroby hepatobiliarnoi systemy: fokus na ratsionalnu hepatotropnu terapiiu // Gastroenterologìa – 2019. – Т. 53, № 3. – S. 188–195. https://doi.org/10.22141/2308-2097.53.3.2019.182866
11. Shmatova O. O. Fizychna reabilitatsiia khvorykh z toksychnymy hepatytamy na statsionarnomu etapi likuvannia. Avtoref. dys. … kand. nauk z fiz. vykh. ta sportu: spets. 24.00.03 «Fizychna reabilitatsiia». – Kyiv, 2014. – 20 p.
12. Kockerling D., Nathwani R., Forlano R., Manousou P., Mullish B. H., Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications // World J. Gastroenterol. – 2019. – V. 25, N 8. – Р. 888–908. https://doi.org/10.3748/wjg.v25.i8.888
13. Lanini S., Ustianowski A., Pisapia R., Zumla A., Ippolito G. Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention // Infect. Dis. Clin. North. Am. – 2019. – V. 33, N 4. – Р. 1045–1062. https://doi.org/10.1016/j.idc.2019.08.004
14. Volkova A. V., Fedosov A. I., Kyslychenko V. S. Marketynhovyi analiz rynku hepatotropnykh likarskykh zasobiv // Zb. nauk. prats spivrob. NMAPO im. P. L. Shupyka. – 2015. – Vip. 24 (5). – S. 294–300.
15. Yevtushko A. S., Herush O. V. Analiz asortymentu hepatotropnykh likarskykh zasobiv na farmatsevtychnomu rynku Ukrainy protiahom 2014–2016 rokiv / Tekhnolohichni ta biofarmatsevtychni aspekty stvorennia likarskykh preparativ riznoi napravlenosti dii. Mat. III Mizhnar. nauk.-prakt. internet-konferentsii, m. Kharkiv, 14–15 lyst. 2017 r. – Kharkiv: NUPh, 2017. – S. 75–76.
16. Marvek Medkhat Musa Istanis. Naukovo-praktychni pidkhody do formuvannia rynkovoho potentsialu hepatotropnykh likarskykh preparativ. Avtoref. dys. … kand. farm. nauk: spets. 15.00.01 «Tekhnolohiia likiv, orhanizatsiia farmatsevtychnoi spravy ta sudova farmatsiia». – Kharkiv, 2019. – 27 s.
17. Herush O. V., Yakovlieva L. V., Tkachova O. V. Hepatotropni zasoby: doslidzhennia asortymentu i sotsialno-ekonomichnoi dostupnosti v Ukraini vprodovzh 2015–2017 rr. // Ukr. biofarmats. zh. – 2019. – Т. 1, № 58. – S. 44–49. https://doi.org/10.24959/ubphj.19.208
18. Kawaguchi I., Chayama K., Gonzalez Y. S. et al. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan // Adv. Ther. – 2020. – V. 37. – Р. 457–476. https://doi.org/10.1007/s12325-019-01166-3
19. Systema doslidzhennia rynku likarskykh zasobiv «Farmstandart» kompanii «Morion». – URL: http://www.pharmstandart.com.ua
20. Morozov A. M., Yakovlieva L. V., Stepanenko A. V. Vyvchennia spozhyvannia likarskykh zasobiv za anatomo-terapevtychno-khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATC/DDDmetodolohiia): metod. rek. – K.: NFaU; DETs MOZ Ukrainy, 2013. – 32 s.
21. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment, 2020. Oslo, 2019. – URL: https://www.whocc.no/filearchive/publications/2020_guidelines_web.pdf
Published
2020-07-09
How to Cite
Iakovlieva, L. V., Bahlai, T. O., & Holub, V. M. (2020). Review for Ukrainian pharmaceutical market of hepatotropic drugs and determining the volumes of their consumption during 2016–2018 years. Farmatsevtychnyi Zhurnal, (3), 3-15. https://doi.org/10.32352/0367-3057.3.20.01
Section
Management of pharmacy